Direct factor Xa inhibitor YM150 for prevention of stroke in subjects with non-valvular atrial fibrillation - a double blind, parallel, dose-finding study in comparison with open label warfarin.

Trial Profile

Direct factor Xa inhibitor YM150 for prevention of stroke in subjects with non-valvular atrial fibrillation - a double blind, parallel, dose-finding study in comparison with open label warfarin.

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Dec 2011

At a glance

  • Drugs Darexaban; Warfarin
  • Indications Embolism and thrombosis; Stroke
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Sep 2010 Primary endpoint results presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology
    • 21 Jan 2009 Actual end date (Oct 2008) added as reported by ClinicalTrials.gov.
    • 21 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top